American Society of Hirudotherapy

Medicinal Leech Therapy in Urology: A PRISMA-Compliant Systematic Review

Battin AO, Hobeika N, Zdilla MJ (2023) · African Journal of Urology · n=12

Review: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Study Profile

Design
PRISMA-compliant systematic review of 12 unique medicinal leech therapy cases in urological contexts (MEDLINE/PubMed)
Pooled sample (n; included studies may overlap)
12
Scope
Medicinal leech therapy across 12 urological cases: 4 post-penile replantation, 2 post-scrotal hematoma, 2 post-neonatal bladder exstrophy repair, 1 refractory priapism, 3 penoscrotal edema in hormone refractory prostate carcinoma
Main result
All 12 cases (100%) reported clinical improvement; venous congestion/hematoma cases noted decreased displaced blood volume; priapism case had decreased pain; penoscrotal edema cases had significant swelling reduction; no complications in 9 adult patients; 3 neonatal patients required blood products

Key Findings

  • First PRISMA-compliant urology-specific leech review
  • 100% reported clinical improvement across 12 cases
  • Diverse indications: replant, hematoma, exstrophy, priapism, edema
  • No complications in 9 adult patients
  • 3 neonatal cases required blood products (volume-related)

Limitations

  • Small case pool (n=12 unique cases)
  • Publication bias toward successful outcomes
  • Heterogeneous indications limit cross-comparison
  • No control groups available
  • PRISMA methodology applied to case-level evidence

Clinical Implications

Battin 2023 establishes leech therapy as a viable urologic adjunct across diverse indications with favorable safety profile in adults. For US clinicians under K040187, this PRISMA review extends device application to refractory priapism, penoscrotal edema, and post-bladder exstrophy congestion contexts beyond the traditional flap-salvage indication. The neonatal blood product requirement highlights age-specific considerations.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.